Archive - GLP-1 Digest

How GLP-1s Are Breaking Life Insurance

Patients look healthy on paper. Two years later, they're high-risk again.

Jun 22 •

Ashwin Sharma, MD

Why Novo Nordisk Won't Beat Eli Lilly

Dividends over R&D is not a good strategy

Jun 15 •

Ashwin Sharma, MD

How a Tiny British Startup Became Silicon Valley's Hottest Acquisition

Tiny British startup? Hottest? How?

Jun 8 •

Ashwin Sharma, MD

What Do GLP-1 Patients Actually Want?

Losing weight is just the beginning

Jun 1 •

Ashwin Sharma, MD

May 2025

Are You Ready for the On-Off Reality of GLP-1s?

Patients will pause, rebound, and return

May 25 •

Ashwin Sharma, MD

Stop Calling GLP-1s a Trend

83 % refills, $2.2 B pill deals, Saudi production lines. The fad died; the utility was born.

May 18 •

Ashwin Sharma, MD

Hims is Quietly Building a Consumer Health Empire

What their Q1 earnings call reveals about the future of D2C healthcare

May 11 •

Ashwin Sharma, MD

Who Wins (and Loses) in Pharma’s Latest GLP-1 Power Play?

Novo's surprising partnerships, disruptive NHS whispers, and a fresh shift in employer economics could redefine the D2C landscape.

May 4 •

Ashwin Sharma, MD

April 2025

March 2025

The Suffering Economy is Over

Weight-loss meds threaten a $300 billion industry built on shame. That’s exactly why we need them.

Mar 13 •

Ashwin Sharma, MD

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts